ReviewJournal of cardiovascular translational research2020
Extracellular Vesicles as Messengers in Atherosclerosis.
Review in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Molecular Interactions Between Vascular Smooth Muscle Cells and Macrophages in Atherosclerosis.Frontiers in cardiovascular medicine · 2021Pooled it
- Bibliometric analysis of research trends on nanotechnology applications in atherosclerosis.Discover nano · 2026Review
- Article
- Vascular Stress Markers Following Inhalation of Heated Tobacco Products: A Study on Extracellular Vesicles.Cardiovascular toxicology · 2025Observational
- Extracellular vesicles in atherosclerosis cardiovascular disease: emerging roles and mechanisms.Frontiers in cardiovascular medicine · 2025Review
- Review
- Extracellular Vesicles in Atherosclerosis: State of the Art.International journal of molecular sciences · 2023Review
- Extracellular vesicles carrying proinflammatory factors may spread atherosclerosis to remote locations.Cellular and molecular life sciences : CMLS · 2022Article
- An Outer Membrane Vesicle-Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability.Advanced healthcare materials · 2022Article
- Emerging Roles of Extracellular Vesicle-Delivered Circular RNAs in Atherosclerosis.Frontiers in cell and developmental biology · 2022Review
- Article
- Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation.Drug delivery · 2021Review
- Design considerations for engineering 3D models to study vascular pathologies in vitro.Acta biomaterialia · 2021Review
- Extracellular Vesicles: Versatile Nanomediators, Potential Biomarkers and Therapeutic Agents in Atherosclerosis and COVID-19-Related Thrombosis.International journal of molecular sciences · 2021Review
- Micro- and Nanosized Substances Cause Different Autophagy-Related Responses.International journal of molecular sciences · 2021Review
- Circulating Extracellular Vesicles As Biomarkers and Drug Delivery Vehicles in Cardiovascular Diseases.Biomolecules · 2021Review
- Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a major cause of cardiovascular diseases. Most cells involved in atherosclerosis can shed extracellular vesicles (EVs). Both atherogenic factors, such as hypoxia and oxidative stress, and atheroprotective factors, such as laminar blood flow, can influence the production of EV shedding. EVs can carry protein, DNA, mRNA, and noncoding RNA and act as mediators or messengers for cell-to-cell communications. EVs have been proven to promote or inhibit atherogenesis under particular circumstances. Therefore, EVs might be targeted for preventing or treating atherosclerotic diseases. The level of circulating EVs has been associated with the presence, progressiveness, or severity of atherosclerosis. Therefore, EVs may be utilized as indexes for diagnosing and grading atherosclerosis. Here, we reviewed the progress concerning the involvements of EVs in atherogenesis and atheroprotection. We also discussed the potential applications of EVs in managing atherosclerotic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.